NovoCure Limited Stock Price, News & Analysis (NASDAQ:NVCR)

$18.15 -0.75 (-3.97 %)
(As of 11/20/2017 04:00 PM ET)
Previous Close$18.90
Today's Range$19.24 - $18.13
52-Week Range$6.00 - $22.30
Volume619,799 shs
Average Volume854,279 shs
Market Capitalization$1.62 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About NovoCure Limited (NASDAQ:NVCR)

NovoCure Limited logoNovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:NVCR
  • CUSIP: N/A
  • Web: www.novocure.com
Debt:
  • Debt-to-Equity Ratio: 0.83%
  • Current Ratio: 5.90%
  • Quick Ratio: 5.30%
Sales & Book Value:
  • Annual Sales: $82.89 million
  • Price / Sales: 19.57
  • Book Value: $1.64 per share
  • Price / Book: 11.07
Profitability:
  • Trailing EPS: ($0.83)
  • Net Income: ($131,840,000.00)
  • Net Margins: -47.45%
  • Return on Equity: -57.68%
  • Return on Assets: -27.35%
Misc:
  • Employees: 460
  • Outstanding Shares: 89,360,000
 

Frequently Asked Questions for NovoCure Limited (NASDAQ:NVCR)

What is NovoCure Limited's stock symbol?

NovoCure Limited trades on the NASDAQ under the ticker symbol "NVCR."

How were NovoCure Limited's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) issued its quarterly earnings data on Thursday, October, 26th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.07. The medical equipment provider had revenue of $50.10 million for the quarter, compared to the consensus estimate of $43.45 million. NovoCure Limited had a negative return on equity of 57.68% and a negative net margin of 47.45%. The company's quarterly revenue was up 130.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.39) earnings per share. View NovoCure Limited's Earnings History.

When will NovoCure Limited make its next earnings announcement?

NovoCure Limited is scheduled to release their next quarterly earnings announcement on Thursday, February, 22nd 2018. View Earnings Estimates for NovoCure Limited.

Where is NovoCure Limited's stock going? Where will NovoCure Limited's stock price be in 2017?

7 equities research analysts have issued 1 year price objectives for NovoCure Limited's stock. Their forecasts range from $14.00 to $34.00. On average, they anticipate NovoCure Limited's stock price to reach $20.86 in the next twelve months. View Analyst Ratings for NovoCure Limited.

What are Wall Street analysts saying about NovoCure Limited stock?

Here are some recent quotes from research analysts about NovoCure Limited stock:

  • 1. According to Zacks Investment Research, "NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. " (11/10/2017)
  • 2. J P Morgan Chase & Co analysts commented, "NVCR’s 1Q report (slides here) was largely uneventful as the co continues to make progress with the Optune launch. 1Q net revenues were $35M vs. consensus of $41M (though we note the cash vs. accrual accounting makes net revenue hard to predict). There were 1,266 active patients on therapy at 1Q-end (+16% q/q), ahead of our 1,226 estimate. We are encouraged by the progress here, though will be looking for momentum to continue to build following recent reimbursement wins, NCCN guidelines, as well as impressive follow-up survival data from the pivotal EF-14 trial." (5/1/2017)

Who are some of NovoCure Limited's key competitors?

Who are NovoCure Limited's key executives?

NovoCure Limited's management team includes the folowing people:

  • William F. Doyle, Executive Chairman of the Board (Age 54)
  • Asaf Danziger, Chief Executive Officer, Director (Age 50)
  • Kinyip Gabriel Leung, Vice Chairman of the Board (Age 53)
  • Yoram Palti M.D., Ph.D., Founder, Director (Age 78)
  • Wilhelmus C. M. Groenhuysen, Chief Financial Officer (Age 59)
  • Michael J. Ambrogi, Chief Operating Officer (Age 53)
  • Eilon D. Kirson M.D., Ph.D., Chief Science Officer and Head of Research and Development (Age 48)
  • Todd Longsworth, General Counsel (Age 42)
  • William T. Burkoth, Independent Director (Age 40)
  • Louis J. Lavigne Jr., Independent Director (Age 69)

Who owns NovoCure Limited stock?

NovoCure Limited's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include StepStone Group LP (1.81%), Frontier Capital Management Co. LLC (0.93%), Peregrine Capital Management LLC (0.71%), Pier Capital LLC (0.31%), Cortina Asset Management LLC (0.29%) and C WorldWide Group Holding A S (0.26%). Company insiders that own NovoCure Limited stock include Asaf Danziger, Eilon D Kirson, Gert L Perlhagen, Michael J Ambrogi, Pomona Capital Vii Fund Invest, Robert J Mylod Jr and Yoram Palti. View Institutional Ownership Trends for NovoCure Limited.

Who sold NovoCure Limited stock? Who is selling NovoCure Limited stock?

NovoCure Limited's stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, StepStone Group LP, Engineers Gate Manager LP, C WorldWide Group Holding A S, River & Mercantile Asset Management LLP, Macquarie Group Ltd. and California State Teachers Retirement System. Company insiders that have sold NovoCure Limited company stock in the last year include Asaf Danziger, Eilon D Kirson, Michael J Ambrogi, Pomona Capital Vii Fund Invest and Yoram Palti. View Insider Buying and Selling for NovoCure Limited.

Who bought NovoCure Limited stock? Who is buying NovoCure Limited stock?

NovoCure Limited's stock was bought by a variety of institutional investors in the last quarter, including Pier Capital LLC, Cortina Asset Management LLC, Hodges Capital Management Inc., Stifel Financial Corp, Essex Investment Management Co. LLC, Ameriprise Financial Inc., Chicago Equity Partners LLC and Dynamic Technology Lab Private Ltd. Company insiders that have bought NovoCure Limited stock in the last two years include Asaf Danziger, Gert L Perlhagen and Robert J Mylod Jr. View Insider Buying and Selling for NovoCure Limited.

How do I buy NovoCure Limited stock?

Shares of NovoCure Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NovoCure Limited's stock price today?

One share of NovoCure Limited stock can currently be purchased for approximately $18.90.

How big of a company is NovoCure Limited?

NovoCure Limited has a market capitalization of $1.62 billion and generates $82.89 million in revenue each year. The medical equipment provider earns ($131,840,000.00) in net income (profit) each year or ($0.83) on an earnings per share basis. NovoCure Limited employs 460 workers across the globe.

How can I contact NovoCure Limited?

NovoCure Limited's mailing address is Le Masurier House, La Rue Le Masurier, SAINT HELIER, JE2 4YE, Jersey. The medical equipment provider can be reached via phone at +44-1534-756700 or via email at [email protected]


MarketBeat Community Rating for NovoCure Limited (NASDAQ NVCR)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  176 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  325
MarketBeat's community ratings are surveys of what our community members think about NovoCure Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for NovoCure Limited (NASDAQ:NVCR)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 6 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $20.86 (14.92% upside)

Consensus Price Target History for NovoCure Limited (NASDAQ:NVCR)

Price Target History for NovoCure Limited (NASDAQ:NVCR)

Analysts' Ratings History for NovoCure Limited (NASDAQ:NVCR)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/20/2017J P Morgan Chase & CoReiterated RatingBuyN/AView Rating Details
10/27/2017WedbushReiterated RatingOutperform$29.00 -> $25.00N/AView Rating Details
9/6/2017MizuhoInitiated CoverageBuy$25.00MediumView Rating Details
7/17/2017Deutsche Bank AGReiterated RatingHold$18.00 -> $19.00LowView Rating Details
5/24/2017Wells Fargo & CompanyUpgradeMarket Perform -> Outperform$15.00HighView Rating Details
4/18/2017AegisReiterated RatingBuy$14.00LowView Rating Details
4/4/2017JMP SecuritiesReiterated RatingOutperform$34.00HighView Rating Details
7/29/2016Barclays PLCLower Price TargetUnderweight$12.00 -> $9.00N/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for NovoCure Limited (NASDAQ:NVCR)

Earnings by Quarter for NovoCure Limited (NASDAQ:NVCR)

Earnings History by Quarter for NovoCure Limited (NASDAQ NVCR)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2018        
10/26/20179/30/2017($0.20)($0.13)$43.45 million$50.10 millionViewN/AView Earnings Details
7/27/20176/30/2017($0.23)($0.24)$42.20 million$38.38 millionViewN/AView Earnings Details
4/27/20173/31/2017($0.25)($0.21)$39.46 million$34.88 millionViewN/AView Earnings Details
2/23/2017Q416($0.39)($0.26)$26.95 million$30.20 millionViewN/AView Earnings Details
11/2/2016Q3 2016($0.42)($0.39)$21.65 million$21.67 millionViewN/AView Earnings Details
7/28/2016Q216($0.37)($0.48)$15.90 million$17.90 millionViewListenView Earnings Details
5/9/2016Q116($0.33)($0.42)$23.65 million$13.10 millionViewN/AView Earnings Details
10/26/2015Q315($2.09)$4.37 million$8.95 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NovoCure Limited (NASDAQ:NVCR)
2017 EPS Consensus Estimate: ($0.62)
2018 EPS Consensus Estimate: ($0.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.26)($0.26)($0.26)
Q3 20171($0.25)($0.25)($0.25)
Q4 20171($0.11)($0.11)($0.11)
Q1 20181($0.09)($0.09)($0.09)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.16)($0.16)($0.16)
Q4 20181($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for NovoCure Limited (NASDAQ:NVCR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for NovoCure Limited (NASDAQ NVCR)

Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 38.55%
Insider Trades by Quarter for NovoCure Limited (NASDAQ:NVCR)
Institutional Ownership by Quarter for NovoCure Limited (NASDAQ:NVCR)

Insider Trades by Quarter for NovoCure Limited (NASDAQ NVCR)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/13/2017Yoram PaltiInsiderSell30,000$17.13$513,900.00View SEC Filing  
11/9/2017Yoram PaltiCTOSell30,000$18.25$547,500.00View SEC Filing  
11/7/2017Yoram PaltiInsiderSell60,000$21.06$1,263,600.00View SEC Filing  
11/6/2017Asaf DanzigerCEOSell6,919$22.00$152,218.00View SEC Filing  
11/3/2017Asaf DanzigerCEOSell2,300$22.00$50,600.00View SEC Filing  
11/3/2017Eilon D KirsonInsiderSell3,400$22.00$74,800.00View SEC Filing  
11/3/2017Michael J AmbrogiCOOSell1,200$22.00$26,400.00View SEC Filing  
11/2/2017Yoram PaltiCTOSell30,000$21.78$653,400.00View SEC Filing  
11/1/2017Asaf DanzigerCEOSell15,866$22.01$349,210.66View SEC Filing  
11/1/2017Eilon D KirsonInsiderSell22,269$22.01$490,140.69View SEC Filing  
11/1/2017Michael J AmbrogiCOOSell24,327$22.01$535,437.27View SEC Filing  
9/25/2017Asaf DanzigerCEOSell900$22.05$19,845.00View SEC Filing  
9/14/2017Asaf DanzigerCEOSell37,272$22.01$820,356.72View SEC Filing  
9/13/2017Asaf DanzigerCEOSell35,500$22.01$781,355.00View SEC Filing  
7/11/2017Asaf DanzigerCEOSell7,383$19.95$147,290.85View SEC Filing  
7/10/2017Asaf DanzigerCEOSell274,359$18.07$4,957,667.13View SEC Filing  
7/6/2017Asaf DanzigerCEOSell160,138$18.14$2,904,903.32View SEC Filing  
7/5/2017Asaf DanzigerCEOSell155,088$18.14$2,813,296.32View SEC Filing  
6/26/2017Pomona Capital Vii Fund InvestMajor ShareholderSell1,072,532$17.35$18,608,430.20View SEC Filing  
6/21/2017Eilon D KirsonInsiderSell66,361$16.78$1,113,537.58View SEC Filing  
6/19/2017Asaf DanzigerCEOSell124,720$15.51$1,934,407.20View SEC Filing  
6/19/2017Eilon D KirsonInsiderSell15,000$15.06$225,900.00View SEC Filing  
6/16/2017Asaf DanzigerCEOSell42,457$15.15$643,223.55View SEC Filing  
6/14/2017Asaf DanzigerCEOSell94,102$15.22$1,432,232.44View SEC Filing  
6/12/2017Asaf DanzigerCEOSell180,601$15.13$2,732,493.13View SEC Filing  
6/12/2017Eilon D KirsonInsiderSell20,956$15.03$314,968.68View SEC Filing  
6/5/2017Yoram PaltiInsiderSell3,825$13.82$52,861.50View SEC Filing  
6/2/2017Yoram PaltiInsiderSell8,000$13.27$106,160.00View SEC Filing  
5/31/2017Yoram PaltiInsiderSell8,000$12.49$99,920.00View SEC Filing  
5/26/2017Yoram PaltiInsiderSell8,000$12.88$103,040.00View SEC Filing  
5/24/2017Yoram PaltiInsiderSell4,000$13.15$52,600.00View SEC Filing  
5/23/2017Yoram PaltiInsiderSell8,000$11.73$93,840.00View SEC Filing  
5/19/2017Yoram PaltiInsiderSell8,000$11.39$91,120.00View SEC Filing  
5/17/2017Yoram PaltiInsiderSell4,000$11.47$45,880.00View SEC Filing  
5/16/2017Yoram PaltiInsiderSell8,000$12.05$96,400.00View SEC Filing  
5/12/2017Yoram PaltiInsiderSell8,000$11.79$94,320.00View SEC Filing  
5/10/2017Yoram PaltiInsiderSell8,000$12.29$98,320.00View SEC Filing  
5/8/2017Yoram PaltiInsiderSell8,000$11.82$94,560.00View SEC Filing  
5/4/2017Yoram PaltiInsiderSell8,000$11.42$91,360.00View SEC Filing  
5/2/2017Yoram PaltiInsiderSell8,000$11.64$93,120.00View SEC Filing  
4/28/2017Yoram PaltiInsiderSell8,000$11.25$90,000.00View SEC Filing  
4/26/2017Yoram PaltiInsiderSell8,000$10.78$86,240.00View SEC Filing  
4/24/2017Yoram PaltiInsiderSell8,000$11.26$90,080.00View SEC Filing  
4/20/2017Yoram PaltiInsiderSell8,000$11.24$89,920.00View SEC Filing  
4/18/2017Yoram PaltiInsiderSell16,000$10.64$170,240.00View SEC Filing  
4/17/2017Yoram PaltiCTOSell4,000$10.77$43,080.00View SEC Filing  
4/13/2017Yoram PaltiCTOSell4,000$10.43$41,720.00View SEC Filing  
4/12/2017Yoram PaltiCTOSell4,000$10.72$42,880.00View SEC Filing  
3/14/2017Gert L PerlhagenDirectorBuy125,000$6.93$866,250.00View SEC Filing  
12/22/2016Michael J AmbrogiCOOSell27,500$8.27$227,425.00View SEC Filing  
12/20/2016Michael J AmbrogiCOOSell20,000$8.62$172,400.00View SEC Filing  
12/19/2016Michael J AmbrogiCOOSell20,000$8.76$175,200.00View SEC Filing  
12/16/2016Michael J AmbrogiCOOSell40,000$8.93$357,200.00View SEC Filing  
12/14/2016Michael J AmbrogiCOOSell40,000$8.97$358,800.00View SEC Filing  
12/12/2016Michael J AmbrogiCOOSell15,000$9.01$135,150.00View SEC Filing  
12/8/2016Michael J AmbrogiCOOSell10,000$8.30$83,000.00View SEC Filing  
12/6/2016Michael J AmbrogiCOOSell10,000$8.24$82,400.00View SEC Filing  
8/5/2016Gert L PerlhagenDirectorSell676,576$1.85$1,251,665.60View SEC Filing  
6/8/2016Michael J AmbrogiCOOSell20,000$12.24$244,800.00View SEC Filing  
3/3/2016Asaf DanzigerCEOBuy10,000$15.00$150,000.00View SEC Filing  
3/3/2016Robert J Mylod JrDirectorBuy20,000$15.78$315,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for NovoCure Limited (NASDAQ NVCR)

Source:
DateHeadline
NovoCure Limited (NVCR) Given "Buy" Rating at J P Morgan Chase & CoNovoCure Limited (NVCR) Given "Buy" Rating at J P Morgan Chase & Co
www.americanbankingnews.com - November 20 at 3:32 PM
Patients Who Used Optune® More Than 90 Percent of the Time Had the Greatest Chance of Survival in Novocure’s EF-14 Trial: A Median Survival of 24.9 Months from Randomization and a Five-Year Survival of 29.3 PercentPatients Who Used Optune® More Than 90 Percent of the Time Had the Greatest Chance of Survival in Novocure’s EF-14 Trial: A Median Survival of 24.9 Months from Randomization and a Five-Year Survival of 29.3 Percent
finance.yahoo.com - November 18 at 9:25 AM
Novocure Shares Jump on Phase 3 Data Analysis -- Biotech MoversNovocure Shares Jump on Phase 3 Data Analysis -- Biotech Movers
finance.yahoo.com - November 18 at 9:25 AM
Estimating The Intrinsic Value Of NovoCure Limited (NVCR)Estimating The Intrinsic Value Of NovoCure Limited (NVCR)
finance.yahoo.com - November 18 at 9:25 AM
FY2017 EPS Estimates for NovoCure Limited Decreased by Analyst (NVCR)FY2017 EPS Estimates for NovoCure Limited Decreased by Analyst (NVCR)
www.americanbankingnews.com - November 17 at 8:30 PM
NovoCure Limited (NVCR) Insider Yoram Palti Sells 30,000 SharesNovoCure Limited (NVCR) Insider Yoram Palti Sells 30,000 Shares
www.americanbankingnews.com - November 14 at 8:05 PM
Novocure Announces 28 Presentations on Tumor Treating Fields from Externally Led Clinical Research and Analysis at 22nd Annual Meeting of the Society for Neuro-OncologyNovocure Announces 28 Presentations on Tumor Treating Fields from Externally Led Clinical Research and Analysis at 22nd Annual Meeting of the Society for Neuro-Oncology
finance.yahoo.com - November 14 at 6:16 AM
ETFs with exposure to Novocure Ltd. : November 13, 2017ETFs with exposure to Novocure Ltd. : November 13, 2017
finance.yahoo.com - November 14 at 6:16 AM
NovoCure Limited (NVCR) CTO Sells $547,500.00 in StockNovoCure Limited (NVCR) CTO Sells $547,500.00 in Stock
www.americanbankingnews.com - November 13 at 5:14 PM
 Analysts Expect NovoCure Limited (NVCR) Will Announce Quarterly Sales of $52.62 Million Analysts Expect NovoCure Limited (NVCR) Will Announce Quarterly Sales of $52.62 Million
www.americanbankingnews.com - November 13 at 8:48 AM
NovoCure Limited (NVCR) Downgraded by Zacks Investment Research to "Hold"NovoCure Limited (NVCR) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - November 13 at 12:20 AM
Zacks: Brokerages Expect NovoCure Limited (NVCR) Will Announce Earnings of -$0.15 Per ShareZacks: Brokerages Expect NovoCure Limited (NVCR) Will Announce Earnings of -$0.15 Per Share
www.americanbankingnews.com - November 11 at 5:30 PM
Novocure Announces 13 Preclinical Presentations Highlighting Data on Tumor Treating Fields’ Mechanism of Action at 22nd Annual Meeting of the Society for Neuro-OncologyNovocure Announces 13 Preclinical Presentations Highlighting Data on Tumor Treating Fields’ Mechanism of Action at 22nd Annual Meeting of the Society for Neuro-Oncology
finance.yahoo.com - November 9 at 7:49 AM
Novocure Announces 10 Presentations on Simulation Studies Aiming to Optimize Treatment Delivery of Tumor Treating Fields at 22nd Annual Meeting of the Society for Neuro-OncologyNovocure Announces 10 Presentations on Simulation Studies Aiming to Optimize Treatment Delivery of Tumor Treating Fields at 22nd Annual Meeting of the Society for Neuro-Oncology
finance.yahoo.com - November 9 at 7:49 AM
Asaf Danziger Sells 6,919 Shares of NovoCure Limited (NVCR) StockAsaf Danziger Sells 6,919 Shares of NovoCure Limited (NVCR) Stock
www.americanbankingnews.com - November 8 at 7:40 PM
NovoCure Limited (NVCR) Insider Yoram Palti Sells 60,000 SharesNovoCure Limited (NVCR) Insider Yoram Palti Sells 60,000 Shares
www.americanbankingnews.com - November 8 at 6:48 PM
Novocure Announces Six Clinical Presentations on Novocure’s Phase 3 Pivotal EF-14 Trial Data in Newly Diagnosed Glioblastoma at 22nd Annual Meeting of the Society for Neuro-OncologyNovocure Announces Six Clinical Presentations on Novocure’s Phase 3 Pivotal EF-14 Trial Data in Newly Diagnosed Glioblastoma at 22nd Annual Meeting of the Society for Neuro-Oncology
finance.yahoo.com - November 7 at 4:28 PM
Michael J. Ambrogi Sells 1,200 Shares of NovoCure Limited (NVCR) StockMichael J. Ambrogi Sells 1,200 Shares of NovoCure Limited (NVCR) Stock
www.americanbankingnews.com - November 6 at 8:22 PM
NovoCure Limited (NVCR) Insider Sells $74,800.00 in StockNovoCure Limited (NVCR) Insider Sells $74,800.00 in Stock
www.americanbankingnews.com - November 6 at 7:30 PM
NovoCure Limited (NVCR) CEO Sells $50,600.00 in StockNovoCure Limited (NVCR) CEO Sells $50,600.00 in Stock
www.americanbankingnews.com - November 6 at 7:30 PM
NovoCure Limited (NVCR) CTO Sells $653,400.00 in StockNovoCure Limited (NVCR) CTO Sells $653,400.00 in Stock
www.americanbankingnews.com - November 6 at 6:58 PM
Michael J. Ambrogi Sells 24,327 Shares of NovoCure Limited (NVCR) StockMichael J. Ambrogi Sells 24,327 Shares of NovoCure Limited (NVCR) Stock
www.americanbankingnews.com - November 2 at 5:40 PM
NovoCure Limited (NVCR) CEO Asaf Danziger Sells 15,866 SharesNovoCure Limited (NVCR) CEO Asaf Danziger Sells 15,866 Shares
www.americanbankingnews.com - November 2 at 5:40 PM
NovoCure Limited (NVCR) Insider Eilon D. Kirson Sells 22,269 SharesNovoCure Limited (NVCR) Insider Eilon D. Kirson Sells 22,269 Shares
www.americanbankingnews.com - November 2 at 5:40 PM
Novocure Ltd. breached its 50 day moving average in a Bullish Manner : NVCR-US : October 31, 2017Novocure Ltd. breached its 50 day moving average in a Bullish Manner : NVCR-US : October 31, 2017
finance.yahoo.com - November 1 at 7:03 AM
ETFs with exposure to Novocure Ltd. : October 30, 2017ETFs with exposure to Novocure Ltd. : October 30, 2017
finance.yahoo.com - October 31 at 7:15 AM
Novocure Ltd. :NVCR-US: Earnings Analysis: Q3, 2017 By the Numbers : October 27, 2017Novocure Ltd. :NVCR-US: Earnings Analysis: Q3, 2017 By the Numbers : October 27, 2017
finance.yahoo.com - October 28 at 8:28 PM
NovoCure Limiteds (NVCR) "Outperform" Rating Reaffirmed at WedbushNovoCure Limited's (NVCR) "Outperform" Rating Reaffirmed at Wedbush
www.americanbankingnews.com - October 28 at 5:32 PM
Novocure Reports Third Quarter 2017 Financial Results and Provides Company UpdateNovocure Reports Third Quarter 2017 Financial Results and Provides Company Update
finance.yahoo.com - October 27 at 8:52 AM
NovoCure reports 3Q lossNovoCure reports 3Q loss
finance.yahoo.com - October 27 at 8:52 AM
Edited Transcript of NVCR earnings conference call or presentation 26-Oct-17 12:00pm GMTEdited Transcript of NVCR earnings conference call or presentation 26-Oct-17 12:00pm GMT
finance.yahoo.com - October 27 at 8:52 AM
NovoCure Limited (NVCR) Announces  Earnings ResultsNovoCure Limited (NVCR) Announces Earnings Results
www.americanbankingnews.com - October 26 at 7:10 PM
$43.26 Million in Sales Expected for NovoCure Limited (NVCR) This Quarter$43.26 Million in Sales Expected for NovoCure Limited (NVCR) This Quarter
www.americanbankingnews.com - October 24 at 4:14 AM
NovoCure (NVCR) Looks Good: Stock Adds 8.3% in Session - NasdaqNovoCure (NVCR) Looks Good: Stock Adds 8.3% in Session - Nasdaq
www.nasdaq.com - October 19 at 7:00 AM
NovoCure Limited (NVCR) Set to Announce Quarterly Earnings on ThursdayNovoCure Limited (NVCR) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - October 19 at 3:34 AM
Novocure Announces Data Presentations at the IASLC 18th World Conference on Lung CancerNovocure Announces Data Presentations at the IASLC 18th World Conference on Lung Cancer
finance.yahoo.com - October 17 at 3:25 AM
First Week of November 17th Options Trading For NovoCure (NVCR)First Week of November 17th Options Trading For NovoCure (NVCR)
www.thestreet.com - October 15 at 2:15 AM
NovoCure Ltd is Now Oversold - Nasdaq.com - NasdaqNovoCure Ltd is Now Oversold - Nasdaq.com - Nasdaq
www.nasdaq.com - October 14 at 6:18 AM
NovoCure Stock Sees Short Interest Drop 15.6%NovoCure Stock Sees Short Interest Drop 15.6%
www.thestreet.com - October 12 at 7:38 AM
Critical Contrast: NovoCure Limited (NVCR) & Insmed (INSM)Critical Contrast: NovoCure Limited (NVCR) & Insmed (INSM)
www.americanbankingnews.com - October 10 at 2:10 AM
Novocure Ltd. – Value Analysis (NASDAQ:NVCR) : October 3, 2017Novocure Ltd. – Value Analysis (NASDAQ:NVCR) : October 3, 2017
finance.yahoo.com - October 5 at 12:48 PM
Zacks: Analysts Anticipate NovoCure Limited (NVCR) Will Post Quarterly Sales of $43.26 MillionZacks: Analysts Anticipate NovoCure Limited (NVCR) Will Post Quarterly Sales of $43.26 Million
www.americanbankingnews.com - October 5 at 5:04 AM
NovoCure Limited (NVCR) Receives Consensus Rating of "Buy" from AnalystsNovoCure Limited (NVCR) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - October 4 at 9:16 AM
Novocure to Report Third Quarter 2017 Financial ResultsNovocure to Report Third Quarter 2017 Financial Results
finance.yahoo.com - October 2 at 7:13 PM
Novocure Ltd. breached its 50 day moving average in a Bearish Manner : NVCR-US : October 2, 2017Novocure Ltd. breached its 50 day moving average in a Bearish Manner : NVCR-US : October 2, 2017
finance.yahoo.com - October 2 at 7:13 PM
NovoCure Limited (NVCR) CEO Sells $19,845.00 in StockNovoCure Limited (NVCR) CEO Sells $19,845.00 in Stock
www.americanbankingnews.com - September 27 at 8:32 PM
Combination of Optune® with Temozolomide Demonstrates Unprecedented Five-Year Survival for Newly Diagnosed Glioblastoma PatientsCombination of Optune® with Temozolomide Demonstrates Unprecedented Five-Year Survival for Newly Diagnosed Glioblastoma Patients
finance.yahoo.com - September 24 at 8:01 PM
Novocure Announces Data Presentations at the American Society for Radiation Oncology’s 2017 Annual MeetingNovocure Announces Data Presentations at the American Society for Radiation Oncology’s 2017 Annual Meeting
finance.yahoo.com - September 22 at 11:57 AM
Analyzing ZIOPHARM Oncology (ZIOP) and NovoCure Limited (NVCR)Analyzing ZIOPHARM Oncology (ZIOP) and NovoCure Limited (NVCR)
www.americanbankingnews.com - September 16 at 10:48 AM
NovoCure Limited (NVCR) CEO Asaf Danziger Sells 35,500 SharesNovoCure Limited (NVCR) CEO Asaf Danziger Sells 35,500 Shares
www.americanbankingnews.com - September 15 at 7:44 PM

Social Media

Financials

Chart

NovoCure Limited (NASDAQ NVCR) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.